Anti‐CD22 and anti‐CD79b antibody‐drug conjugates preferentially target proliferating B cells

BACKGROUND AND PURPOSE: CD22 and CD79b are cell‐surface receptors expressed on B‐cell‐derived malignancies such as non‐Hodgkin's lymphoma (NHL). An anti‐mitotic agent, monomethyl auristatin E, was conjugated to anti‐CD22 and anti‐CD79b antibodies to develop target‐specific therapies for NHL. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Fuh, Franklin K, Looney, Caroline, Li, Dongwei, Poon, Kirsten A, Dere, Randall C, Danilenko, Dimitry M, McBride, Jacqueline, Reed, Chae, Chung, Shan, Zheng, Bing, Mathews, William Rodney, Polson, Andrew, Prabhu, Saileta, Williams, Marna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368047/
https://www.ncbi.nlm.nih.gov/pubmed/28009435
http://dx.doi.org/10.1111/bph.13697

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368047/
https://www.ncbi.nlm.nih.gov/pubmed/28009435
http://dx.doi.org/10.1111/bph.13697

Ejemplares similares